CCCC FY 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+1.0% YoY

Gross Profit

$28M77.8% margin

Operating Income

-$104M-290.7% margin

Net Income

-$105M-292.1% margin

EPS (Diluted)

$-1.27

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$99M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$359M

Total Liabilities

$102M

Stockholders' Equity

$257M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$36M	+1.0%
Gross Profit	$28M	$36M	-21.4%
Operating Income	-$104M	-$120M	+12.6%
Net Income	-$105M	-$105M	+0.3%